AGTR1 and left ventricular hypertrophy: These findings may reflect valsartan’s pharmacological characteristics, including its selective blockade of AT1 receptors and its effects on reducing left ventricular hypertrophy and improving endothelial function, as well as its frequent application in patients with significant cardiovascular risks [27].